Adia Med Reports No Serious Adverse Events in First Autism Study Cohort
Adia Med said no serious adverse events occurred in the first cohort of its randomized Phase 1/2 pediatric ASD study. Two mild rashes linked to the glutathione spray resolved after discontinuation; enrollment and follow-up continue.